Neural stem cells: you are buying expansion headroom, and one consent restriction can end a project

A vial of neural stem cells and a vial of differentiated neurons cost roughly the same money and buy completely different things. The neuron vial is a fixed quantity of terminal cells. The NSC vial is a quantity of cells plus an unstated amount of expansion headroom, you can passage it, and how many times you can passage it before the population drifts is the entire economic case for buying it.

No supplier surveyed publishes that number as a release specification. Not iXCells, not Axol. Neither states a guaranteed passage count or a guaranteed population doubling figure for their NSC products. So the buyer is purchasing the one property that justifies the purchase, and it is not on the datasheet.

That is the buying problem. Everything below is about how to close it.

The price table

Two patterns worth extracting, both checkable against the table.

The disease premium is not flat, and it is not flat in the same way at each supplier. At iXCells, both disease lines, sporadic ALS and SOD1 A4V, sit at $1,155.00 against $1,040.00 wild type, an 11 percent uplift applied uniformly. At Axol the uplift varies by line: the ApoE variant is 61 percent above the $745.00 wild-type SKU, and the Huntington’s CAG125 line is 108 percent above it.

That difference tells you something about how each supplier thinks about disease material. A flat uplift prices a manufacturing overhead. A variable uplift prices scarcity, or the difficulty of maintaining a specific line, or its demand. Neither is wrong, but it means you cannot generalise a disease premium from one supplier to another, and a budget built on “add roughly 15 percent for a mutant line” will be wrong by a factor of seven on the Huntington’s line.

The wild-type gap between suppliers is large. $745.00 at Axol against $1,040.00 at iXCells is a 40 percent spread on the nominally equivalent product. Axol also states a minimum vial content of at least 1.5 million cells, which iXCells does not publish on the storefront listing. That combination, lower price and a published minimum count, makes the comparison lean one way on public information, with the caveat that the products are not identical and the counting conventions may differ.

What expandability is actually worth

The reason to buy progenitors rather than neurons is arithmetic: if you can passage a vial four or five times, the effective cost per differentiated neuron falls dramatically below the cost of buying terminal cells. If you can passage it twice before the population drifts, it does not.

Nobody sells you the number. What you can do is make the risk explicit.

Ask for the passage number on receipt. This is the base your expansion budget is counted from and every supplier can tell you. Get it in writing before the order rather than reading it off a tube label after delivery.

Ask what the supplier’s own protocol expects. Suppliers run these cells internally. Ask how many passages their own characterisation covers and at what passage their marker data was generated. That is not a guarantee, but a supplier that says “we characterise to passage five” is telling you something useful, and a supplier that will not answer is telling you something too.

Assume drift and check for it. Progenitor populations are not homogeneous and their composition changes with culture. A 2025 eLife study documents changes in neural progenitor lineage composition during astrocytic differentiation of human iPSCs (PMC12563561), a direct demonstration that what is in the dish shifts as the culture proceeds. Budget a marker panel at the passage you actually use, not just at receipt.

Do not spread a study across passages without controlling for it. If arm one runs at passage three and arm two at passage seven, passage is a variable in your result whether or not it is in your methods section. Either run all arms at the same passage or bank an intermediate stock so you can.

The full comparison between buying progenitors and expanding versus buying terminal neurons is in the buy-versus-differentiate cost model.

Regional identity: the specification that is easiest to under-specify

“Neural stem cell” and “neural progenitor cell” are used loosely and cover populations with quite different regional identities.

The published work makes the distinction concrete. Spinal cord GABAergic neural progenitors are described as a distinct product-like entity in a 2026 Cell Proliferation paper (PMC12877944). Work on the axial identity of spinal cord neural progenitor grafts (PMC13024784) addresses regional identity directly as an experimental variable. A STAR Protocols article covers the generation and xenotransplantation of iPSC-derived neural progenitors (PMC12874554), where the identity of the grafted population is the whole question.

The procurement consequence: if your downstream target is a specific neuronal subtype, the progenitor’s regional identity is a gating specification, not a detail. A forebrain-patterned progenitor is a poor starting point for a spinal motor neuron protocol. Ask which regional markers the supplier’s characterisation covers, and if the product page does not state a regional identity, treat the absence as an open question rather than as a default.

Disease lines, and the control you must order at the same time

Every disease NSC SKU in the table has an implied comparator, and the comparator is a separate purchase at a separate price with a separate lead time.

The failure mode is well known and still common: order the mutant line now because it is the interesting one, order the control next quarter when the budget refreshes, and end up comparing two lots manufactured months apart, possibly from different production runs, possibly at different passages.

Two rules that prevent it:

Order both arms in the same transaction. If the budget will not cover both, the honest conclusion is that the budget will not cover the experiment.

Prefer an isogenic comparator to a healthy-donor comparator where one exists. A different person is not a control for a mutation. The reasoning, the fee tiers and the licensing consequences are in disease-model and isogenic iPSC line pairs.

One further caution that applies specifically to edited lines: clonal variability is a real confounder, and work in Scientific Reports shows that wild-type heterogeneity itself contributes to clonal variability in genome-edited cells (PMC9616811). A single edited clone against a single parental clone is one comparison, not a result. Where the finding matters, more than one independent clone per arm is the defensible design.

The consent restriction that propagates

This is the item on the page most likely to end a project, and it costs nothing to check.

Axol’s ax0018 donor lineage carries a documented sequencing restriction on ethical-consent grounds, and that restriction propagates to several downstream products derived from the lineage. A buyer who plans to sequence the cells, RNA-seq, exome, whole genome, or any published genomic analysis, should be routed away from that lineage before the order is placed.

The structural problem is that consent scope does not appear on a price list and rarely appears on a product comparison. It attaches to a donor, it travels with every product derived from that donor, and it is discoverable in supplier documentation if you go looking. Buyers usually do not go looking, because it does not occur to them that a cell they bought might come with a restriction on what they may measure.

The check is one line in the enquiry: “State any consent or use restrictions attached to this donor lineage, including any restriction on sequencing or genomic analysis, and confirm whether they propagate to derived products.” Send it every time. It costs one sentence and it is the only question on this page that can invalidate a completed experiment retrospectively.

Related, and worth asking in the same breath: the licence position on anything commercial. That is covered in cell line licensing for commercial use.

Buy progenitors, or buy the differentiation as a service

There is a third route that buyers frequently forget to price.

Buy NSCs and differentiate in-house when you have the protocol, the media, the incubator time and a technician who has done it before. The economics are good and you keep the expansion optionality.

Buy terminal neurons when you need a defined quantity of a defined subtype on a defined date and the differentiation is not the interesting part. See human iPSC cortical neurons.

Buy the differentiation as a contract service when the protocol exists but not in your building. This is a real market with real providers and it is covered in custom iPSC differentiation. The comparison that matters is not vial price against vial price; it is total programme cost including the weeks of technician time that in-house differentiation consumes, and that comparison quite often favours the service.

QC checklist

• Lot-specific certificate of analysis, reviewed before you commit.
• Passage number on receipt, in writing, before the order.
• Guaranteed minimum viable cell count, and whether the figure is at freeze or post-thaw.
• Post-thaw viability specification and the assay used.
• NSC or NPC marker panel run on this lot, distinguished from representative product-page data.
• Regional identity markers, where a regional identity is required.
• The passage at which the supplier’s characterisation was performed, which bounds what the marker data actually covers.
• Medium and coating package the characterisation depends on, by catalogue number.
• Sterility, mycoplasma and identity testing with methods named.
• Karyotype documentation where the supplier provides it, particularly for lines you intend to expand substantially.
• Donor consent and use-restriction documentation, explicitly including any restriction on sequencing.
• Shipping format and receiving procedure, confirmed against what your site can accept.

Specification checklist for an NSC or NPC quote

• Genotype and disease background, named precisely, with zygosity where relevant.
• The matched control arm, ordered in the same transaction, and whether it is isogenic or a healthy donor.
• Regional identity required, stated against markers rather than by label.
• Target differentiated cell type, because it determines which progenitor is correct and whether you should be buying differentiation as a service instead.
• Guaranteed minimum viable cell count and the counting convention.
• Passage on receipt and the expansion you intend to perform, stated in the enquiry so the supplier can tell you whether it is realistic.
• Downstream sequencing intent, stated explicitly, so consent restrictions surface before the purchase order rather than at publication.
• Media and coating package, and whether the quote includes it.
• Delivery week, and whether the lot is in stock or awaiting a production run. Disease lines are more often the latter.
• Licence terms for anything downstream that will be sold rather than published.

Where to go next

The datasheet, unit, lead time and QC scope, is at ipsc-neural-stem-cells. If you would rather buy terminal cells, human iPSC cortical neurons is the comparison, and the buy-versus-differentiate cost model does the arithmetic on both routes. For matched controls, disease-model and isogenic iPSC line pairs.

How we can help

Two things on this page are worth outsourcing. The first is getting passage number, characterisation passage and the supplier’s own expansion experience out of two vendors in comparable form, because none of it is published. The second is the consent question, which we ask on every enquiry as standard and which buyers almost never ask themselves.

Tell us the genotype, the control arm, the target subtype and whether you intend to sequence, and we will source quotes, normalise the counting conventions, and put the use restrictions in writing before anyone raises a purchase order.